Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1820)	7/9/2007 12:51:22 PM
From: Jibacoa	Respond to of 3722

BIOM OK to put on a watch list ? <g> Message 23685043 Bernard

To: Jibacoa who wrote (1820)	7/13/2007 1:33:26 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

MITI Is trying to go over the $3 level for the 3rd time this week.<g> bigcharts.marketwatch.com It announced Wednesday that TRACON has started the treatment of the first cancer patient in a PI trial with TRC093. (MITI gave TRACON the license for it in March.) TRC093 is a first-in-class humanized monoclonal antibody that inhibits angiogenesis and tumor cell growth by binding cleaved collagen.It has shown activity, as monotherapy or when combined with chemotherapy, in pre-clinical studies of melanoma, breast and pancreatic cancer. TRACON is also trying TRC093 for AMD. (MITI developed it up to the filing and acceptance of the IND.) biz.yahoo.com Bernard